Business
Proposed Placing and Acquisitions
Vulcan Two Group plc is proposing to acquire three UK ePharmacy companies, CloudRx Holdings Limited, Hyperdrug Pharmaceuticals Ltd, and Webmed Pharmacy Ltd, for a total maximum consideration of approximately £41.7 million, with £37.1 million payable in cash. To fund this, the company plans to raise £40 million through an institutional placing of new ordinary shares at 200 pence per share. These acquisitions constitute a reverse takeover, requiring shareholder approval. The enlarged group is projected to generate over £35 million in revenue, with a significant portion being recurring. The placing price represents a 9.1% discount to the previous day's closing price. Disclaimer*
About this update from Vulcan Two Group Plc
[{"type":"text","content":"\n\nTHIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN ARE RESTRICTED AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.\nTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014 (AS AMENDED) AS IT FORMS PART OF THE DOMESTIC LAW OF THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 (AS AMENDED) (\"MAR\").\nFOR IMMEDIATE RELEASE\n \n \n26 February 2026\nVulcan Two Group plc\n(the \"Company\" or \"Vulcan Two\")\n \nProposed acquisition of CloudRx Holdings Limited\nProposed acquisition of Hyperdrug Pharmaceuticals Ltd\nProposed acquisition of Webmed Pharmacy Ltd\nProposed Placing\nReadmission of the Enlarged Share Capital to trading on AIM\n \nVulcan Two Group plc, the company aiming to create the UK's leading regulated ePharmacy through buy-and-build, announces that it has conditionally agreed to acquire three companies in the UK ePharmacy market, being CloudRx Holdings Limited (\"CloudRx\"), Hyperdrug Pharmaceuticals Ltd (\"Hyperdrug\") and Webmed Pharmacy Ltd (\"Webmed\") (each of Hyperdrug, Webmed and CloudRx, being a \"Target\") (and together, the \"Acquisitions\"). The total maximum consideration for the Acquisitions is approximately £41.7 million, of which approximately £37.1 million is payable in cash on completion of the Acquisitions.\n \nTo satisfy the cash consideration payable for the Acquisitions, the Company also announces that it proposes to raise gross proceeds of £40 million, by way of an institutional placing of new Ordinary Shares (the \"Placing\") at a price of 200 pence per share (the \"Placing Price\"). The Placing will be conducted by way of an accelerated bookbuild (\"ABB\"), which will be launched immediately following this Announcement in accordance with the terms and conditions set out in Appendix B of this Announcement.\n \nThe Acquisitions, individually and collectively, constitute a Reverse Takeover pursuant to Rule 14 of the AIM Rules for Companies and, as such, are, together with the Placing, subject to Shareholder approval at a General Meeting. An Admission Document containing details of the Acquisitions and the Placing and containing a noti...